FI119723B - Suihkukuivattu erytropoietiini - Google Patents
Suihkukuivattu erytropoietiini Download PDFInfo
- Publication number
- FI119723B FI119723B FI972557A FI972557A FI119723B FI 119723 B FI119723 B FI 119723B FI 972557 A FI972557 A FI 972557A FI 972557 A FI972557 A FI 972557A FI 119723 B FI119723 B FI 119723B
- Authority
- FI
- Finland
- Prior art keywords
- rhepo
- spray
- dried
- drying
- chemically synthesized
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title description 13
- 102000003951 Erythropoietin Human genes 0.000 title description 10
- 108090000394 Erythropoietin Proteins 0.000 title description 10
- 229940105423 erythropoietin Drugs 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 15
- 239000007921 spray Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 210000001995 reticulocyte Anatomy 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000004108 freeze drying Methods 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012527 feed solution Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 150000001860 citric acid derivatives Chemical class 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35794794A | 1994-12-16 | 1994-12-16 | |
US35794794 | 1994-12-16 | ||
US9516416 | 1995-12-15 | ||
PCT/US1995/016416 WO1996018647A1 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
Publications (3)
Publication Number | Publication Date |
---|---|
FI972557A0 FI972557A0 (fi) | 1997-06-16 |
FI972557A FI972557A (fi) | 1997-08-14 |
FI119723B true FI119723B (fi) | 2009-02-27 |
Family
ID=23407689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI972557A FI119723B (fi) | 1994-12-16 | 1997-06-16 | Suihkukuivattu erytropoietiini |
Country Status (19)
Country | Link |
---|---|
US (2) | US6001800A (de) |
EP (1) | EP0805822B2 (de) |
JP (1) | JP4039686B2 (de) |
CN (1) | CN1117762C (de) |
AT (1) | ATE265468T1 (de) |
AU (1) | AU697287B2 (de) |
CA (1) | CA2207615C (de) |
DE (1) | DE69532970T3 (de) |
DK (1) | DK0805822T4 (de) |
ES (1) | ES2219672T5 (de) |
FI (1) | FI119723B (de) |
HU (1) | HU222370B1 (de) |
IL (1) | IL116085A (de) |
NO (1) | NO319895B1 (de) |
NZ (1) | NZ298981A (de) |
PT (1) | PT805822E (de) |
TW (1) | TW425287B (de) |
WO (1) | WO1996018647A1 (de) |
ZA (1) | ZA9510708B (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539574A1 (de) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
US6542481B2 (en) | 1998-06-01 | 2003-04-01 | Tantivy Communications, Inc. | Dynamic bandwidth allocation for multiple access communication using session queues |
US6081536A (en) * | 1997-06-20 | 2000-06-27 | Tantivy Communications, Inc. | Dynamic bandwidth allocation to transmit a wireless protocol across a code division multiple access (CDMA) radio link |
US6151332A (en) | 1997-06-20 | 2000-11-21 | Tantivy Communications, Inc. | Protocol conversion and bandwidth reduction technique providing multiple nB+D ISDN basic rate interface links over a wireless code division multiple access communication system |
EP0913177A1 (de) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
US7496072B2 (en) | 1997-12-17 | 2009-02-24 | Interdigital Technology Corporation | System and method for controlling signal strength over a reverse link of a CDMA wireless communication system |
US9525923B2 (en) | 1997-12-17 | 2016-12-20 | Intel Corporation | Multi-detection of heartbeat to reduce error probability |
US8175120B2 (en) | 2000-02-07 | 2012-05-08 | Ipr Licensing, Inc. | Minimal maintenance link to support synchronization |
US7936728B2 (en) | 1997-12-17 | 2011-05-03 | Tantivy Communications, Inc. | System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system |
US7394791B2 (en) | 1997-12-17 | 2008-07-01 | Interdigital Technology Corporation | Multi-detection of heartbeat to reduce error probability |
US6222832B1 (en) | 1998-06-01 | 2001-04-24 | Tantivy Communications, Inc. | Fast Acquisition of traffic channels for a highly variable data rate reverse link of a CDMA wireless communication system |
US8134980B2 (en) | 1998-06-01 | 2012-03-13 | Ipr Licensing, Inc. | Transmittal of heartbeat signal at a lower level than heartbeat request |
US7773566B2 (en) | 1998-06-01 | 2010-08-10 | Tantivy Communications, Inc. | System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system |
US6526034B1 (en) | 1999-09-21 | 2003-02-25 | Tantivy Communications, Inc. | Dual mode subscriber unit for short range, high rate and long range, lower rate data communications |
US8155096B1 (en) | 2000-12-01 | 2012-04-10 | Ipr Licensing Inc. | Antenna control system and method |
US6954448B2 (en) | 2001-02-01 | 2005-10-11 | Ipr Licensing, Inc. | Alternate channel for carrying selected message types |
US7551663B1 (en) | 2001-02-01 | 2009-06-23 | Ipr Licensing, Inc. | Use of correlation combination to achieve channel detection |
ES2284858T3 (es) | 2001-02-02 | 2007-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina. |
ES2626289T3 (es) | 2001-06-13 | 2017-07-24 | Intel Corporation | Método y aparatos para la transmisión de señal de latido a un nivel más bajo que la solicitud de latido |
CA2498319A1 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
US8575332B2 (en) | 2003-11-14 | 2013-11-05 | Chugai Seiyaku Kabushiki Kaisha | Crosslinked polysaccharide microparticles and method for their preparation |
AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
JP5425398B2 (ja) | 2004-12-22 | 2014-02-26 | アンブレツクス・インコーポレイテツド | 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用 |
EP1951890A4 (de) | 2005-11-16 | 2009-06-24 | Ambrx Inc | Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren |
EP2615108B1 (de) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
JP2010510794A (ja) | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
ATE554785T1 (de) | 2007-03-30 | 2012-05-15 | Ambrx Inc | Modifizierte fgf-21 polypeptide und ihre verwendung |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
MX2010007728A (es) | 2008-01-15 | 2010-12-21 | Abbott Gmbh & Co Kg | Composiciones proteinicas en polvo y metodos para elaborar las mismas. |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
PT104350A (pt) | 2009-01-23 | 2010-07-23 | Hovione Farmaci Ncia S A | Processo de isolamento de tigeciclina |
BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
MX349301B (es) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Polipéptidos de somatotropina bovina modificados y sus usos. |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
JP5913367B2 (ja) | 2011-01-05 | 2016-04-27 | ホスピーラ インコーポレイテッド | バンコマイシンの噴霧乾燥 |
US9566241B2 (en) | 2012-02-21 | 2017-02-14 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
EA036697B1 (ru) | 2014-10-24 | 2020-12-09 | Бристол-Майерс Сквибб Компани | Модифицированные полипептиды fgf-21 и их применение |
CN104984323B (zh) * | 2015-06-12 | 2018-05-01 | 北京四环生物制药有限公司 | 注射用重组人促红素冻干粉针剂 |
CN105311624A (zh) * | 2015-11-23 | 2016-02-10 | 哈药集团生物工程有限公司 | 一种含有重组人促红素的药物组合物 |
FI3849614T3 (fi) | 2018-09-11 | 2024-02-08 | Ambrx Inc | Interleukiini-2-polypeptidikonjugaatteja ja niiden käyttöjä |
JP2022512746A (ja) | 2018-10-19 | 2022-02-07 | アンブルックス,インコーポレイテッド | インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用 |
BR112021015832A2 (pt) | 2019-02-12 | 2022-01-18 | Ambrx Inc | Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57149228A (en) * | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
-
1995
- 1995-11-21 IL IL11608595A patent/IL116085A/xx not_active IP Right Cessation
- 1995-12-15 CN CN95197638.9A patent/CN1117762C/zh not_active Expired - Lifetime
- 1995-12-15 PT PT95943452T patent/PT805822E/pt unknown
- 1995-12-15 WO PCT/US1995/016416 patent/WO1996018647A1/en active IP Right Grant
- 1995-12-15 DK DK95943452.3T patent/DK0805822T4/da active
- 1995-12-15 ES ES95943452T patent/ES2219672T5/es not_active Expired - Lifetime
- 1995-12-15 AU AU44713/96A patent/AU697287B2/en not_active Expired
- 1995-12-15 AT AT95943452T patent/ATE265468T1/de active
- 1995-12-15 EP EP95943452A patent/EP0805822B2/de not_active Expired - Lifetime
- 1995-12-15 ZA ZA9510708A patent/ZA9510708B/xx unknown
- 1995-12-15 HU HU9800996A patent/HU222370B1/hu active IP Right Grant
- 1995-12-15 DE DE69532970T patent/DE69532970T3/de not_active Expired - Lifetime
- 1995-12-15 JP JP51929496A patent/JP4039686B2/ja not_active Expired - Lifetime
- 1995-12-15 CA CA2207615A patent/CA2207615C/en not_active Expired - Lifetime
- 1995-12-15 NZ NZ298981A patent/NZ298981A/xx not_active IP Right Cessation
-
1996
- 1996-06-06 TW TW085106816A patent/TW425287B/zh not_active IP Right Cessation
- 1996-12-15 US US08/894,023 patent/US6001800A/en not_active Expired - Lifetime
-
1997
- 1997-06-13 NO NO19972725A patent/NO319895B1/no not_active IP Right Cessation
- 1997-06-16 FI FI972557A patent/FI119723B/fi not_active IP Right Cessation
-
1999
- 1999-10-12 US US09/415,726 patent/US6235710B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI119723B (fi) | Suihkukuivattu erytropoietiini | |
US7235253B2 (en) | Powder containing physiologically active peptide | |
AU627174B2 (en) | Human growth hormone formulation | |
Kobayashi et al. | Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats | |
US5589167A (en) | Excipient stabilization of polypeptides treated with organic solvents | |
US5919443A (en) | Stable lyophilized pharmaceutical preparations of G-CSF | |
US20060074011A1 (en) | Compositions providing for increased IGF-I solubility | |
KR100705997B1 (ko) | 안정화된 hgf 동결건조제제 및 그 제조방법 | |
NZ535008A (en) | Polymer-based compositions for sustained release | |
IE64738B1 (en) | Stabilized gonadotropin containing preparations | |
CA2118655C (en) | Parathyroid hormone-containing emulsion for nasal administration | |
CA2234724A1 (en) | Stable pharmaceutical forms of administration containing parathyroid hormone | |
CN101578106A (zh) | Hgf制剂 | |
WO1993023065A1 (en) | Pharmaceutical compositions containing il-6 | |
AU8109491A (en) | Stable pharmaceutical compositions containing a fibroblast growth factor | |
CN108606955A (zh) | 培化西海马肽的药用组合物及其制备方法 | |
US5093127A (en) | Preparation of fr115224 substrate for parenteral administration | |
MXPA97004504A (en) | Aspected eritropoyetin | |
EP1028748A1 (de) | Zusammensetzung um die löslichkeit von igf-i zu erhöhen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 119723 Country of ref document: FI |
|
MA | Patent expired |